Hypersensitivity to the active substance or to any of the excipients.
Patients with severe renal impairment (CrCl < 30 ml/min) (see "Dosage & Administration").
Active clinically significant bleeding.
Hepatic impairment or liver disease expected to have any impact on survival.
Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole and dronedarone (see Interactions).
Prosthetic heart valve replacement requiring anticoagulant treatment (see Pharmacology under Actions).
Lesion or condition, if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
Concomitant treatment with any other anticoagulant agent e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see "Dosage & Administration") or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see "Interactions").